Memelin

Exemestane, the active ingredient in Memelin, is an aromatase inhibitor presented as an oral formulation for oral use. It treats postmenopausal breast cancer by reducing estrogen production.

GNH USA supplies Memelin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Exemestane is an aromatase inhibitor used in hormonal therapy for breast cancer. - Postmenopausal breast cancer: Used as adjuvant therapy to lower recurrence after surgery. - Hormone‑receptor positive metastatic breast cancer: Provides disease control after prior endocrine therapy failure. - Estrogen‑dependent tumor prevention: Inhibits estrogen synthesis to limit tumor proliferation.

Exemestane may cause a range of adverse reactions.

Common Side Effects: - Hot flashes: Sudden feeling of warmth and sweating. - Joint pain: Musculoskeletal discomfort, especially in knees and hips. - Fatigue: Persistent tiredness not relieved by rest. - Nausea: Mild to moderate upset stomach.

Serious or Rare Side Effects: - Severe liver injury: Elevated liver enzymes or hepatitis requiring medical attention. - Thromboembolic events: Deep vein thrombosis or pulmonary embolism that may be life‑threatening.

Before initiating therapy, consider the following precautions. - Assess liver function: Obtain baseline hepatic enzymes and monitor periodically. - Monitor bone health: Evaluate risk of osteoporosis and consider calcium/vitamin D supplementation. - Evaluate cardiovascular risk: Watch for signs of thrombosis, especially in high‑risk patients. - Avoid use in pregnancy: Contraindicated in women of childbearing potential; ensure effective contraception. - Store at ambient temperature: Keep below 25°C in the original pack, protect from moisture.

Exemestane can interact with several drug classes.

Major Interactions (Avoid): - Estrogen‑containing hormone therapy: Negates the aromatase‑inhibiting effect. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): Decrease plasma concentrations of exemestane.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): May increase bleeding tendency; monitor INR. - Selective serotonin reuptake inhibitors: Can exacerbate hot flashes. - Tamoxifen: Potential antagonistic effect; clinical efficacy should be monitored.